|
1
|
Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation.
|
Genome Biol
|
2004
|
15.15
|
|
2
|
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.
|
J Clin Invest
|
2010
|
2.87
|
|
3
|
Uncovering growth-suppressive MicroRNAs in lung cancer.
|
Clin Cancer Res
|
2009
|
2.19
|
|
4
|
Retinoids in cancer therapy and chemoprevention: promise meets resistance.
|
Oncogene
|
2003
|
2.02
|
|
5
|
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.
|
Cancer Res
|
2007
|
1.81
|
|
6
|
Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.
|
Clin Cancer Res
|
2004
|
1.68
|
|
7
|
A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.
|
J Natl Cancer Inst
|
2005
|
1.67
|
|
8
|
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.
|
Proc Natl Acad Sci U S A
|
2007
|
1.61
|
|
9
|
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
|
Cancer Prev Res (Phila)
|
2011
|
1.61
|
|
10
|
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.
|
Clin Cancer Res
|
2002
|
1.61
|
|
11
|
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity.
|
J Exp Med
|
2011
|
1.41
|
|
12
|
Bexarotene and erlotinib for aerodigestive tract cancer.
|
J Clin Oncol
|
2005
|
1.30
|
|
13
|
G0S2 is an all-trans-retinoic acid target gene.
|
Int J Oncol
|
2008
|
1.23
|
|
14
|
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
|
Clin Cancer Res
|
2004
|
1.16
|
|
15
|
UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
|
Proc Natl Acad Sci U S A
|
2002
|
1.16
|
|
16
|
Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia.
|
J Biol Chem
|
2004
|
1.14
|
|
17
|
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
|
Clin Cancer Res
|
2009
|
1.10
|
|
18
|
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.
|
Cancer Res
|
2012
|
1.09
|
|
19
|
UBE1L causes lung cancer growth suppression by targeting cyclin D1.
|
Mol Cancer Ther
|
2008
|
1.09
|
|
20
|
Cyclin degradation for cancer therapy and chemoprevention.
|
J Cell Biochem
|
2007
|
1.07
|
|
21
|
Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity.
|
Cancer Res
|
2011
|
1.05
|
|
22
|
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
|
Clin Cancer Res
|
2007
|
1.04
|
|
23
|
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.
|
Oncogene
|
2003
|
1.04
|
|
24
|
High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.
|
Cancer Res
|
2009
|
0.99
|
|
25
|
Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.
|
Cancer Prev Res (Phila)
|
2010
|
0.99
|
|
26
|
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
27
|
Anaphase catastrophe is a target for cancer therapy.
|
Clin Cancer Res
|
2011
|
0.97
|
|
28
|
Involvement of microRNAs in lung cancer biology and therapy.
|
Transl Res
|
2011
|
0.96
|
|
29
|
Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
|
Cancer Res
|
2010
|
0.96
|
|
30
|
Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention.
|
Cancer Res
|
2004
|
0.95
|
|
31
|
Cyclin D1 as a target for chemoprevention.
|
Lung Cancer
|
2003
|
0.95
|
|
32
|
UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.
|
Mol Cancer Ther
|
2008
|
0.94
|
|
33
|
Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting.
|
BMC Cancer
|
2009
|
0.92
|
|
34
|
Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2.
|
Gene
|
2002
|
0.92
|
|
35
|
Lung cancer prevention: the guidelines.
|
Chest
|
2003
|
0.91
|
|
36
|
Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity.
|
Biochim Biophys Acta
|
2005
|
0.91
|
|
37
|
Evidence for the ubiquitin protease UBP43 as an antineoplastic target.
|
Mol Cancer Ther
|
2012
|
0.91
|
|
38
|
Evidence for tankyrases as antineoplastic targets in lung cancer.
|
BMC Cancer
|
2013
|
0.90
|
|
39
|
Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia.
|
J Natl Cancer Inst
|
2007
|
0.89
|
|
40
|
Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.
|
Cancer Res
|
2005
|
0.89
|
|
41
|
Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.
|
ScientificWorldJournal
|
2009
|
0.87
|
|
42
|
Retinoid targets in cancer therapy and chemoprevention.
|
Cancer Biol Ther
|
2003
|
0.86
|
|
43
|
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.
|
Blood
|
2013
|
0.85
|
|
44
|
The retinoic acid paradox in cancer chemoprevention.
|
J Natl Cancer Inst
|
2006
|
0.83
|
|
45
|
Uncovering novel targets for cancer chemoprevention.
|
Recent Results Cancer Res
|
2007
|
0.82
|
|
46
|
Repression of cyclin D1 as a target for germ cell tumors.
|
Int J Oncol
|
2007
|
0.82
|
|
47
|
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
|
Mol Cancer Ther
|
2013
|
0.80
|
|
48
|
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
|
Int J Oncol
|
2012
|
0.80
|
|
49
|
Retinoid chemoprevention trials: cyclin D1 in the crosshairs.
|
Cancer Prev Res (Phila)
|
2009
|
0.79
|
|
50
|
Nonclassical retinoids and lung carcinogenesis.
|
Clin Lung Cancer
|
2005
|
0.78
|
|
51
|
Gene profiling uncovers retinoid target genes.
|
Methods Mol Biol
|
2007
|
0.78
|
|
52
|
Fenretinide activates a distinct apoptotic pathway.
|
J Natl Cancer Inst
|
2004
|
0.78
|
|
53
|
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.
|
Chemotherapy
|
2012
|
0.78
|
|
54
|
Repression of exogenous gene expression by the retinoic acid target gene G0S2.
|
Int J Oncol
|
2013
|
0.77
|
|
55
|
Clinical link between p53 and angiogenesis in lung cancer.
|
J Clin Oncol
|
2002
|
0.77
|
|
56
|
Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition.
|
J Clin Oncol
|
2003
|
0.75
|
|
57
|
Tissue microarrays for hypothesis generation.
|
J Natl Cancer Inst
|
2004
|
0.75
|